Bayer and Orion's darolutamide, a novel oral androgen receptor antagonist for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), has met its primary endpoint in the ARAMIS phase III clinical trial, shwoing that the drug significantly extended metastasis-free survival compared to placebo. The safety profile and the tolerability of darolutamide observed in the ARAMIS trial were consistent with previously published data on darolutamide.
Read more: http://www.pharmatimes.com/news/bayer,_orion_drug_shows_strong_results_in_prostate_cancer_1256853